DE69834658T2 - Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität - Google Patents

Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität Download PDF

Info

Publication number
DE69834658T2
DE69834658T2 DE69834658T DE69834658T DE69834658T2 DE 69834658 T2 DE69834658 T2 DE 69834658T2 DE 69834658 T DE69834658 T DE 69834658T DE 69834658 T DE69834658 T DE 69834658T DE 69834658 T2 DE69834658 T2 DE 69834658T2
Authority
DE
Germany
Prior art keywords
use according
administration
amifostine
aminothiol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69834658T
Other languages
German (de)
English (en)
Other versions
DE69834658D1 (de
Inventor
Martin Blue Bell STOGNIEW
S. David Tucson ALBERTS
H. Edward Skokie KAPLAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
University of Arizona
Arizona's Public Universities
Original Assignee
MedImmune LLC
University of Arizona
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25533362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69834658(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune LLC, University of Arizona, Arizona's Public Universities filed Critical MedImmune LLC
Application granted granted Critical
Publication of DE69834658D1 publication Critical patent/DE69834658D1/de
Publication of DE69834658T2 publication Critical patent/DE69834658T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69834658T 1997-12-09 1998-12-09 Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität Expired - Lifetime DE69834658T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US987550 1997-12-09
US08/987,550 US5994409A (en) 1997-12-09 1997-12-09 Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
PCT/US1998/026096 WO1999029312A1 (en) 1997-12-09 1998-12-09 Methods for treatment of neuro- and nephro-disorders and therapeutic toxicities using aminothiol compounds

Publications (2)

Publication Number Publication Date
DE69834658D1 DE69834658D1 (de) 2006-06-29
DE69834658T2 true DE69834658T2 (de) 2007-05-03

Family

ID=25533362

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834658T Expired - Lifetime DE69834658T2 (de) 1997-12-09 1998-12-09 Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität

Country Status (13)

Country Link
US (7) US5994409A (enExample)
EP (2) EP1039887B1 (enExample)
JP (2) JP2001525359A (enExample)
CN (1) CN1161113C (enExample)
AT (1) ATE326956T1 (enExample)
AU (1) AU739068B2 (enExample)
BR (1) BR9813524A (enExample)
CA (1) CA2313089C (enExample)
DE (1) DE69834658T2 (enExample)
DK (1) DK1039887T3 (enExample)
ES (1) ES2260857T3 (enExample)
PT (1) PT1039887E (enExample)
WO (1) WO1999029312A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
AU2000239101A1 (en) * 2000-03-22 2001-10-03 Neopharm, Inc. A method of administering liposomal encapsulated taxane
EP1328253B1 (en) * 2000-04-26 2006-03-22 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
AU2001271310B2 (en) * 2000-06-14 2005-10-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Inc. Phytoestrogenic Isoflavone Compositions, Their Preparation and Use Thereof for Protection Against and Treatment of Radiation Injury
EP1365803A2 (en) * 2000-08-30 2003-12-03 Oregon Health and Science University Chemoprotectant for gastric toxicity
MXPA03004546A (es) * 2000-11-22 2003-09-10 Rxkinetix Inc Tratamiento de mucositis.
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
JP2005510471A (ja) * 2001-09-24 2005-04-21 トスク インコーポレーティッド 減少した毒性のシスプラチン製剤及びそれを使用する方法
CN100391941C (zh) * 2001-12-07 2008-06-04 海门慧聚药业有限公司 一种胺基硫醇及其硫代衍生物
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
US7981928B2 (en) 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
AU2003285128A1 (en) * 2002-10-31 2004-05-25 Oregon Health And Science University Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
WO2004069224A2 (en) * 2003-02-03 2004-08-19 Neopharm, Inc. Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs
US20040198841A1 (en) * 2003-03-13 2004-10-07 Oregon Health & Science University Use of thiol-based compositions in ameliorating mucosal injury
US8580321B2 (en) * 2003-12-02 2013-11-12 The Cleveland Clinic Foundation Method for reducing the effects of chemotherapy using flagellin related polypeptides
US20050187608A1 (en) * 2004-02-24 2005-08-25 O'hara Michael D. Radioprotective compound coating for medical devices
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20060121016A1 (en) * 2004-10-18 2006-06-08 Lee Raphael C Methods and compositions for treatment of free radical injury
US20070082858A1 (en) * 2004-12-21 2007-04-12 Oregon Health & Science University Methods and compositions for the prevention of toxic side effects of aminoglycoside medications
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
NZ568288A (en) * 2005-11-28 2012-02-24 Verrow Pharmaceuticals Inc Compositions comprising a a cyclodextrin and a nephrotoxic anticancer drug
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
EP2010166B1 (en) * 2006-04-17 2013-11-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Organic disulfide antiretroviral agents
US9585849B2 (en) 2006-04-17 2017-03-07 The Burlington Hc Research Group, Inc. Broad spectrum antiviral and methods of use
US8138227B2 (en) * 2006-07-06 2012-03-20 Trustees Of Dartmouth College Method for inhibiting or reversing non-enzymatic glycation
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
WO2008060441A2 (en) * 2006-11-09 2008-05-22 Scidose Llc Stable amifostine liquid concentrate
US20080253997A1 (en) * 2007-03-27 2008-10-16 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
WO2009069133A2 (en) * 2007-11-28 2009-06-04 Hadasit Medical Research Services And Development Ltd. Methods for the treatment of radiation or chemotherapy-induced tissue damage
ES2476602T3 (es) * 2008-03-14 2014-07-15 Bionumerik Pharmaceuticals, Inc. Composiciones y métodos quimioprotectores
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
CN101347412B (zh) * 2008-09-02 2011-07-27 大连美罗药业股份有限公司 三水合氨磷汀结晶冻干制剂及其制备方法
US9376473B2 (en) 2011-01-10 2016-06-28 Cleveland Biolabs, Inc. Use of Toll-Like Receptor agonist for treating cancer
US20140050728A1 (en) * 2011-01-28 2014-02-20 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EP3011339A4 (en) * 2013-06-18 2017-01-25 Aminomedix Inc. Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
ES2816630T3 (es) 2014-07-30 2021-04-05 Genome Prot Inc Composiciones de flagelina y usos
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
CN114072381B (zh) * 2019-06-13 2024-02-27 上海科州药物研发有限公司 氨基硫醇类化合物作为脑神经或心脏保护剂的用途
CN114712350B (zh) * 2021-12-28 2024-04-12 中国医学科学院放射医学研究所 Dttz在制备预防、治疗化疗损伤药物中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
US4424216A (en) * 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
US4742050B1 (en) 1982-08-17 1994-06-28 Alpha Therapeutic Corp Sensitization of hypoxic tumor cells and control of growth thereof
US4656034A (en) 1985-05-20 1987-04-07 Survival Technology, Inc. Absorption enhancing agents
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
MX168078B (es) 1987-04-15 1993-05-03 Freezone Pty Ltd Rompedor de ceja de llantas
US5091180A (en) 1987-11-20 1992-02-25 Administrators Of The Tulane Educational Fund Protection against rhabdomyolysis-induced nephrotoxicity
DE3888541T2 (de) * 1987-12-22 1994-06-23 U S Bioscience Blue Bell Verbesserung der toxizitätskurven in der chemotherapie.
US5112954A (en) 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
WO1990014007A1 (en) * 1989-05-24 1990-11-29 U.S. Bioscience Method for protection from azt side effects and toxicity
US5167947A (en) 1989-10-26 1992-12-01 Southwest Research Institute Enhancement of absorption of radioprotective drugs
US5217964A (en) 1991-01-23 1993-06-08 Merrell Dow Pharmaceuticals Inc. Polyamine thiols as radioprotective agents
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
US5869338A (en) * 1992-03-13 1999-02-09 Arch Development Corporation Method for protection against genotoxic mutagenesis
US5567686A (en) * 1992-03-13 1996-10-22 Arch Development Corporation Method for protection against genotoxic mutagenesis
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5618823A (en) 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
SG47101A1 (en) * 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
DE4234257A1 (de) * 1992-10-10 1994-04-14 Roehm Gmbh Verfahren zur Herstellung von Thiol(meth)acrylaten
HUT74005A (en) 1993-02-23 1996-10-28 Merrell Pharma Inc Polyamine derivatives as radioprotective agents and pharmaceutical compositions containing them
US5824664A (en) * 1993-03-26 1998-10-20 U.S. Bioscience, Inc. Suppression of HIV expression by organic thiophosphate
CA2124021A1 (en) 1993-05-21 1994-11-22 John Samonides Sr. Adhesive for labels and the like
DE69411271T2 (de) 1993-05-26 1998-11-05 Merrell Pharma Inc N-alkylthiopolyaminderivate als radioprotektive mittel
CA2099070A1 (en) 1993-06-23 1994-12-24 Nelson Mak Process and apparatus for deinking wastepaper with molten fatty acid
US5467947A (en) * 1994-04-08 1995-11-21 Metra Electronics Corporation Mounting kit for mounting one of several types of audio equipment in an automotive dashboard
US5846958A (en) * 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
GB9504995D0 (en) * 1995-03-11 1995-04-26 Zeneca Ltd Compositions
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
US5974409A (en) * 1995-08-23 1999-10-26 Microsoft Corporation System and method for locating information in an on-line network
AU7143196A (en) * 1995-09-25 1997-04-17 Samir Chachoua Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US6110891A (en) 1996-06-21 2000-08-29 Alizyme Therapeutics Ltd. Lectin compositions and uses thereof
US5866591A (en) 1996-09-11 1999-02-02 Glaxo Wellcome Inc. Stable formulations of remifentanil
US6573253B2 (en) * 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US5919934A (en) 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy
FR2761606B1 (fr) 1997-04-08 1999-05-14 Cird Galderma Utilisation de derives aminothiolesters dans le domaine pharmaceutique
US6284259B1 (en) * 1997-11-12 2001-09-04 The Procter & Gamble Company Antimicrobial wipes which provide improved residual benefit versus Gram positive bacteria
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
WO1999030705A1 (en) 1997-12-16 1999-06-24 William Darwin Garner Reduction of uv induced skin cancer by topical amines
JPH11240252A (ja) 1997-12-22 1999-09-07 Tdk Corp 光記録媒体
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6054622A (en) 1998-12-18 2000-04-25 Alliedsignal Inc Aromatic hydroxythiol synthesis using diazonium salts
US6075053A (en) 1999-02-09 2000-06-13 Bionumerik Pharmaceuticals, Inc. Method of reducing or reversing neuropathy
US6489312B1 (en) * 1999-06-15 2002-12-03 Medimmune Oncology, Inc. Pharmaceutical formulations comprising aminoalkyl phosphorothioates

Also Published As

Publication number Publication date
EP1537861A3 (en) 2005-06-15
JP2001525359A (ja) 2001-12-11
AU1718499A (en) 1999-06-28
PT1039887E (pt) 2006-10-31
EP1537861A2 (en) 2005-06-08
BR9813524A (pt) 2002-02-19
DK1039887T3 (da) 2006-09-11
WO1999029312A1 (en) 1999-06-17
ATE326956T1 (de) 2006-06-15
US20020132795A1 (en) 2002-09-19
US7105575B2 (en) 2006-09-12
CA2313089A1 (en) 1999-06-17
CN1283994A (zh) 2001-02-14
EP1039887A1 (en) 2000-10-04
CN1161113C (zh) 2004-08-11
EP1039887A4 (en) 2003-01-15
US5994409A (en) 1999-11-30
EP1039887B1 (en) 2006-05-24
US20060270636A1 (en) 2006-11-30
US20130090312A1 (en) 2013-04-11
ES2260857T3 (es) 2006-11-01
US20060040903A1 (en) 2006-02-23
US6586476B1 (en) 2003-07-01
US20110166108A1 (en) 2011-07-07
AU739068B2 (en) 2001-10-04
CA2313089C (en) 2010-10-12
JP2006188532A (ja) 2006-07-20
DE69834658D1 (de) 2006-06-29

Similar Documents

Publication Publication Date Title
DE69834658T2 (de) Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
RU2394580C2 (ru) Способы лечения митохондриальных нарушений
DE69928410T2 (de) Selenium enthaltende zusammensetzung zur behandlung von systemischen entzündungssyndromen
DE69822659T2 (de) Formulierungen und Verfahren zur Verminderung der Toxizität von Anti-Neoplastischen Mitteln
DE60118172T2 (de) Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
EP0543015B1 (en) Composition, method and kit for potentiating antitumor activity and for curing tumor
DE69429806T2 (de) Pharmazeutische zusammensetzungen zur prävention und behandlung von krebserkrankungen und verfahren für ihre herstellung
DE69821498T2 (de) Verwendung von amifostin
JP2025071293A (ja) ミトコンドリア障害を処置するための方法
JP2010510973A (ja) 心筋組織の壊死を処置するためのホスホエノールピルビン酸誘導体の使用
DE60222383T2 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
EP0374096A1 (de) 2&#39;,3&#39;-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
EP1711462A1 (de) Prolinderivate als pharmazeutische wirkstoffe in der tumortherapie
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
DE60011060T2 (de) Virus behandlung
EP0990441A1 (en) A drug for treating diabetic nephrosis
WO2005056005A1 (de) Chp-gemcitabin-kombinationsmittel und ihre verwendung als antitumorwirkstoffe
WO2012120082A1 (de) Adenosin und seine derivate zur verwendung in der schmerztherapie
WO2004047832A1 (de) Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
AT505367A1 (de) Tumorhemmende ruthenium und osmium- thiosemicarbazonatokomplexe
DE60313976T2 (de) Pharmazeutische zubereitung enthaltend palladiumkomplexverbindungen
MXPA00005668A (en) Methods for treatment of neuro- and nephro-disorders and therapeutic toxicities using aminothiol compounds
DE3688742T2 (de) 2,2-Diphenoxy-N,N-dimethylaminoäthan zur Verbesserung der Sauerstoffversorgung des Gehirns.
EP0654269A1 (en) Medicinal composition for inhibiting cancer metastasis to liver and medicinal composition for curing hepatoma
TOTHENIC et al. Calcium hydrogen phosphate. Source

Legal Events

Date Code Title Description
8364 No opposition during term of opposition